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Editor’s Note
Clinical Perspectives in Hepatology aims to engage
experts with opinions supporting differing perspectives
on the management of a case. Typically, the case repre-
sents an area of debate or evolving practice in clinical
hepatology. The case described by Drs. Wigg, Chin-
naratha, and Registered Nurse Wundke provides an
opportunity to discuss the opportunities and challenges
associated with chronic disease management models
for patients with endstage liver disease.
Chronic Disease Management (CDM) is a patient-
centered approach to healthcare delivery that emphasizes
proactive, longitudinal care between visits. Most health-
care systems are still based on acute illness disease models
established at the beginning of the 20th century. In con-
trast, chronic illnesses now account for more than 75% of
total healthcare expenditures.1 The episodic, symptom-
driven nature of healthcare systems is poorly structured to
manage this increasing burden of chronic conditions.
Chronic liver failure (CLF) is one such condition, with a
median time from diagnosis to death of 10 years, high
morbidity, and frequent hospitalizations.2,3 In similar con-
ditions such as heart failure, advances in CDM have sub-
stantially improved patient outcomes. These advances
include relatively simple concepts such as patient educa-
tion, medication reconciliation, and telephone manage-
ment between visits.4 Recent pilot data suggest that similar
interventions might also improve outcomes in cirrhosis.5,6
An Australian randomized controlled pilot trial
(RCT) did not demonstrate significant differences in
the hospital admission rates, severity of liver disease, or
quality of life.5 However, benefits in outpatient clinic
attendance and quality of care were observed. A second
nonrandomized Italian study of 100 patients found
reduced hospitalization, mortality, and costs in the
intervention group.6 The following case report pro-
vides a demonstration of CDM principles and how
they can be applied to a CLF patient. The response to
the case and discussion offers an approach to advance
the field of CDM models for CLF.
Case Presentation by Drs. Wigg,
Chinnaratha, and Registered Nurse Wundke
A 38-year-old female first presented to our hospital
in 1998 with alcohol intoxication and benzodiazepine
overdose. The following 10 years were characterized by
multiple presentations to the emergency department,
some requiring prolonged in-patient hospital stays.
The main indications for admission were related to
alcoholic hepatitis and polypharmacy overdose with
suicidal intent. Her chronic alcohol abuse, chronic
hepatitis C infection, and depression could not be cur-
tailed by either general practitioners or hospital consul-
tants due to chronic nonadherence with medications,
counseling sessions, and out-patient visits.
In late 2008 she presented with recurrent falls and
hematemesis. Assessment showed grade 3 encephalop-
athy, jaundice, and Model for Endstage Liver Disease
(MELD) score of 38. Gastroscopy showed bleeding
esophageal varices, which were banded. She was man-
aged with nasogastric feeding and supportive measures.
Prior to discharge, she was enrolled into a CDM
program comprised of coordinated case management
by a nurse, supervised by a hospital-based hepatologist.
Specific examples of interventions included: regular
home visits, frequent telephone reviews, rapid access to
care pathway by way of call to a nurse mobile phone,
patient action plans for ascites and encephalopathy,
and medication blister packs.
Hospital usage following enrolment is shown in
Figs. 1 and 2. The initial year postenrolment showed
ongoing high levels of emergency room presentations
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and inpatient hospital days. However, there were dra-
matic declines in these indices for the following 3
years. The patient’s attendance at alcohol counseling
sessions, psychiatry, and outpatient clinic visits
improved, along with better medication compliance.
Alcohol abstinence was achieved and has been main-
tained for 2 years and the current MELD score is 11.
Dr. Wigg and Colleagues’ Perspective
While it is intuitive to believe that models that
have been successfully used for other chronic diseases
will work in CLF, this should not be assumed. CLF
may be a more challenging disease for CDM inter-
ventions, due to the heterogeneity of etiologies and
clinical manifestations, the severity of the disease, and
the frequent association with substance abuse. As sug-
gested by this report, one of the key interventions
required for success is case-management—
characterized by frequent, accessible, and long-term
contacts between the patient and coordinators to help
overcome many of the structural barriers that prevent
effective interactions with clinicians in both hospital
and primary care. This arrangement can improve
therapeutic relationships for the patient from which
can flow greater engagement with multidisciplinary
teams, improved self-management, and improved
adherence with evidence-based therapies. The case
also suggests the need for long-term commitment in
order to achieve benefits, which may not be seen in
early phases of the intervention.
Another possibility to consider is that increased early
hospitalization may be a consequence of improved
access to care and an indicator of quality care.7 Perhaps
increased early hospitalization is required to help keep
sick patients alive, and will translate downstream into
relative mortality reductions. For this reason mortality
is likely to be the key endpoint in CDM studies of
cirrhosis.
Alternative approaches to care redesign have been
studied in cirrhosis. The “Care Management Program”
and “Day Hospital” model in which investigations are
performed, reviewed, and care plans formulated, all
during a 1-day admission, has shown promise in a non-
randomized single-center study.6 The availability of a
day hospital facility for day admissions such as para-
centesis, frequently required by cirrhosis patients, is also
likely to improve the efficiency of hospital utilization.
Greater involvement of primary care physicians also
has potential to improve patient care. Traditional
hospital-centered models led by gastroenterologists
usually fail to provide adequate education and support
of primary care physicians, with whom patients spend
the majority of their healthcare time. Models that pro-
vide greater collaboration and education of primary
healthcare clinicians have shown benefit in the treat-
ment of hepatitis C patients8 and should be incorpo-
rated into future CDM models in CLF. Practical
examples of this could include videoconferencing
between hospital and primary care teams during care
plan formulation and discharge planning.
Dr. Volk’s Perspective
Although CDM holds enormous promise, the case
presented by Dr. Wigg and colleagues highlights the
difficulties with implementing disease management in
clinical practice. One obvious barrier to CDM is the
payment structure of healthcare systems, which rarely
cover proven treatments that are not pharmaceutical or
procedural in nature. The personnel effort described in
this case was funded through a clinical trial, and such
resources are not currently available to most healthcare
providers. The introduction of Accountable Care
Organizations in the United States will hopefully
Fig. 1. Emergency department (ED) presentations pre- and
postenrolment.
Fig. 2. Days spent in hospital pre- and postenrolment.
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provide health systems with financial incentives to pay
for CDM interventions, through shared savings of any
resultant decrease in healthcare expenditures.9
A second, more fundamental, barrier is translating
results from clinical trials into practice. Unlike the pre-
scription of a new pill, implementation of CDM inter-
ventions require setting up new protocols and training
staff, and can be lost in translation from one clinical set-
ting to another. I suspect the patient described in this
case benefited from a highly skilled and experienced hepa-
tology nurse, and such individuals do not grow on trees!
How, then, can the field of hepatology move for-
ward with CDM? I believe we need to distinguish
between clinical trials, implementation trials, and qual-
ity improvement. Traditional RCTs focus on testing
specific interventions in a scientifically rigorous man-
ner, but do not test how the intervention is formulated
and delivered. Unlike a pill, CDM interventions can-
not be mass-produced in a factory and shipped all
over the world. Therefore, CDM trials should prob-
ably borrow from the field of Implementation Science,
which focuses not only on effectiveness of the inter-
vention but also on the effectiveness of the implemen-
tation process.10 For example, if the intervention
includes telephone management by a nurse, then the
intervention should include training protocols and
scripts, and the study should specifically measure the
effectiveness of training inexperienced nurses to admin-
ister the intervention. Finally, even interventions with
proven effectiveness and proven implementation meth-
ods may need to be adjusted to fit different clinical
settings. Here is where quality improvement comes in.
Just as many hepatology programs track their rates of
sustained virological response (SVR) to antiviral ther-
apy for hepatitis C and adjust their protocols accord-
ingly, programs implementing CDM protocols should
monitor for metrics of effectiveness—such as improve-
ments in patient knowledge or self-efficacy.11
Dr. Wigg and Colleagues’ Reply
We thank Dr. Volk for raising the above practical
questions. CDM model implementation will be associ-
ated with costs (coordinators, improved adherence,
improved survival). It is therefore critical that future
studies rigorously evaluate the incremental cost effective-
ness of these models relative to usual care. Such analysis
will enable us to understand whether there are cost sav-
ings or that increased costs are associated with acceptable
thresholds of cost per quality adjusted life year. Estab-
lishing cost effectiveness in clinical trials is likely to be a
helpful driver of change to current funding models of
healthcare with movement towards financial incentives
for management of complex chronic diseases, such as
payment for video-conferencing and care planning.
Translating results from clinical trials of CDM into
real-life practice will be a significant challenge for this
form of complex treatment. The design of trials with
generalizability to routine care will therefore be a pri-
ority. This will require multicenter trials and testing of
the model in a variety of different clinical settings,
including the common setting of community hospitals
where hospital care is led by internal physicians with-
out dedicated gastroenterology/hepatology training.
Implementation of CDM models will also be helped
by a more thorough understanding of the critical ele-
ments of successful models and protocolization of
these elements. Examples of useful protocols used in
our pilot trial were two self-management action plans
for ascites and encephalopathy. Clearly the develop-
ment of standardized training processes for inexper-
ienced care coordinators, covering CDM and self-
management, will be required. Understanding and
standardization of critical care processes will hopefully
lead to robust CDM models, which will be less
dependent on the individual skills of coordinators.
Dr. Volk also perceptively identifies the further prob-
lem of monitoring the effectiveness of CDM interven-
tions in CLF performed outside of clinical trials. At
their core, successful CDM models aim to improve
patient outcomes by way of improvements in patient
education, self-management, and access to quality care.
We would suggest some of the following “process
metrics” as indicators of improved patient engagement
and successful implementation: medication adherence,
improved self-management as assessed by validated
tools,12 and attendance at planned outpatient care.
Combined Authors Recommendations for
CDM in Cirrhosis
1. CDM models are likely to be effective in CLF, but
the unique challenges of this condition require that
high-quality randomized studies are performed.
2. Studies of CDM in cirrhosis must be appropriately
powered for clinically relevant endpoints including
mortality and cost effectiveness, be conducted in
clinically relevant settings, and provide sufficient
details about the nature of the intervention.
3. Translation of findings from such trials into routine
clinical practice will require standardization of care
processes and training, measurement of implemen-
tation success, and flexibility to adjust to different
healthcare systems.
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